No Data
No Data
Jianfeng Group (600668.SH): Subsidiaries do not produce synthetic biological materials
Gelonghui, May 17丨Jianfeng Group (600668.SH) said on the investor interactive platform that its subsidiary Jianfeng Health produces plant-derived rhodiola extract and does not produce synthetic biological raw materials.
Zhejiang Jianfeng's Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug
China's National Medical Products Administration approved the application of Zhejiang Jianfeng Group's (SHA:600668) unit, Jianfeng Pharmaceutical, to register raw drug ingredient imatinib mesylate for
Jianfeng Group (600668.SH): Imatinib mesylate obtains approval notice for application for marketing of chemical raw materials
Gelonghui on May 13 丨 Jianfeng Group (600668.SH) announced that Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Notice of Approval of the Chemical Ingredient Marketing Application” from the State Drug Administration regarding the chemical ingredient imatinib mesylate. Imatinib mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor with antitumor activity.
Jianfeng Group's Pharma Unit Gets Nod to Sell Glaucoma Eye Drops
Zhejiang Jianfeng Pharmaceutical, a unit of cement products manufacturer Zhejiang Jianfeng Group (SHA:600668), obtained approval from China's National Medical Products Administration to produce and ma
Zhejiang Jianfeng Group's (SHSE:600668) Soft Earnings Are Actually Better Than They Appear
Soft earnings didn't appear to concern Zhejiang Jianfeng Group Co., Ltd.'s (SHSE:600668) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
Jianfeng Group (600668.SH): Net profit of 2,4283 million yuan in the first quarter decreased by 89.51% year-on-year
Gelonghui, April 29丨Jianfeng Group (600668.SH) released its report for the first quarter of 2024, achieving operating income of 602 million yuan, a year-on-year decrease of 0.93%; net profit attributable to shareholders of listed companies was 2,4283 million yuan, a year-on-year decrease of 89.51%; and basic earnings per share were 0.0071 yuan.
No Data